H.R. 315 — Introduced in House

I 113th CONGRESS 1st Session H. R. 315 IN THE HOUSE OF REPRESENTATIVES January 18, 2013 Mrs. Emerson introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To provide for the placement of certain synthetic drugs on Schedule I under the Controlled Substances Act. 1. Short title This Act may be cited as the Synthetic Cathinones Control Act of 2013. 2. Addition of synthetic drugs to Schedule I of the Controlled Substances Act (a) In general Notwithstanding any other provision of the Controlled Substances Act (21 U.S.C. 801 et seq.), the Attorney General shall, not later than 60 days after the date of the enactment of this Act, issue a final order that schedules the following substances on schedule I under section 202(c) of that Act (21 U.S.C. 812(c)): (1) 3,4-methylenedioxymethcathinone (meth­yl­one). (2) Naphthylpyrovalerone (naphyrone). (3) 4-fluoromethcathinone (flephedrone). (4) 4-methoxymethcathinone (methedrone; Bk–PMMA). (5) Ethcathinone (N-ethylcathinone). (6) 3,4-methylenedioxyethcathinone (ethylone). (7) Beta-keto-N-methyl-3,4-benzo­di­oxy­oly­bu­tan­amine (butylone). (8) N,N-dimethylcathinone (metamfepramone). (9) Alpha-pyrrolidinopropiophenone (alpha-PPP). (10) 4-methoxy-alphapyrrolidinopropiophenone (MOPPP). (11) 3,4-meth­yl­ene­di­oxy­alpha­pyrrol­idino­pro­pio­phe­none (MDPPP). (12) Alpha-pyrrolidinovalerophenone (alpha-PVP). (13) 6,7-dihydro-5H-indeno[5,6-d][1,3]dioxol-6-amine (MDAI). (14) 3-fluoromethcathinone. (15) 4′-methyl-α-pyrrolidinobutiophenone (MPBP). (b) Conforming amendment To remove deadwood Subsection (c) of section 202 of the Controlled Substances Act (21 U.S.C. 802) is amended to read as follows: (c) Cross reference to Schedules of Controlled Substances Schedules I, II, III, IV, and V shall consist of the drugs and other substances (by whatever official name, common or usual name, chemical name, or brand name designated) that are set forth in the respective schedules in part 1308 of title 21, Code of Federal Regulations, as they may be amended from time to time, or in any successor regulation. .